Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib + cetuximab in EGFR exon 20 insertion-positive non-small-cell lung cancer
NL-OMON55757Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and cetuximab in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Disease control rate at 18 weeks. Started Jan 2019; status: active, not recruiting.
02
Drugs
afatinibcetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55757.